26 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
10
Ending by 2030
Dec 2027
Next term end
15
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends no later than May 2030 · Medium confidence
Also notable
Ends Mar 2031 · High confidence
Also notable
Ends Mar 2031 · High confidence
Reduced Size Self-Delivering Rnai Compounds
US 8,796,443
Cited by 139 later US patents, top 5% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
RNA Interference in Ocular Indications
US 9,095,504
Cited by 106 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
RNA Interference in Dermal and Fibrotic Indications
US 9,340,786
Cited by 87 later US patents, top 5% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2031.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality (US 11,667,915) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
- 2 fees due Jan 7 to 14, 2027 · next Jan 7
- 1 fee due Feb 4, 2027The maintenance fee for RNA Interference in Ocular Indications (US 9,095,504) comes due Feb 4, 2027. Unpaid by Aug 4, 2027, it lapses early.
- 2 fees due May 3 to 19, 2027 · next May 3
- 1 fee due Sep 12, 2027The maintenance fee for Methods for Treating Aging and Skin Disorders Using Nucleic Acids Targeting Tyr or MMP1 (US 11,926,828) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 17, 2026
- 1 term has ended since Aug 17, 2026
What they patent
The 5 largest of its 15 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| RNA Interference in Ocular Indications | 4 in force | to Apr 2031 |
| Reduced Size Self-Delivering Rnai Compounds (2013) | 3 in force | to Jun 2031 |
| Reduced Size Self-Delivering Rnai Compounds (2011) | 3 in force | to May 2030 |
| RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality | 3 in force | to Feb 2030 |
| Methods for Treating Aging and Skin Disorders Using Nucleic Acids Targeting Tyr or MMP1 | 2 in force | to Sep 2036 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,872,118 | Sirna and Methods of Manufacture In force · High confidence | In force | High confidence | |
| US 10,131,904 | Modified Rnai Polynucleotides and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,175,289 | Reduced Size Self-Delivering Rnai Compounds In force · Medium confidence | In force | Medium confidence | |
| US 10,774,330 | Reduced Size Self-Delivering Rnai Compounds In force · Medium confidence | In force | Medium confidence | |
| US 10,167,471 | Inhibition of PCSK9 Through Rnai In force · High confidence | In force | High confidence | |
| US 9,745,574 | RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality In force · High confidence | In force | High confidence | |
| US 10,479,992 | RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality In force · Medium confidence | In force | Medium confidence | |
| US 11,667,915 | RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality In force · Medium confidence | In force | Medium confidence | |
| US 8,796,443 | Reduced Size Self-Delivering Rnai Compounds In force · Medium confidence | In force | Medium confidence | |
| US 9,074,211 | Inhibition of MAP4K4 Through Rnai In force · High confidence | In force | High confidence |
Also on record, not counted in the 26: 1 patent in force now held by others · 19 patents ended · 6 applications pending · 14 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.